HemoShear Therapeutics, LLC
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From HemoShear Therapeutics, LLC
Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.
Plus deals involving Lilly/Daiichi Sankyo, Humianigen/KPM Tech, Telix/China Grand, Appili/Fujifilm, BioInvent/CASI, Osotec/Adel, Neumentum/Nuance, Takeda/HemoShear and Quantum Genomics/Qilu.
Takeda's global deal for one of US RNAi specialist's lead assets follows recent promising clinical results in serious disorder with no current therapeutic options.
Takeda’s collaboration with the private UK biotech includes NASH and other liver disorders. Reliance will take on Amazon in the India pharmacy space with acquisition of Netmeds.
Drug Discovery Tools
- Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.